IL283414A - Methods of treating conditions related to the s1p1 receptor - Google Patents

Methods of treating conditions related to the s1p1 receptor

Info

Publication number
IL283414A
IL283414A IL283414A IL28341421A IL283414A IL 283414 A IL283414 A IL 283414A IL 283414 A IL283414 A IL 283414A IL 28341421 A IL28341421 A IL 28341421A IL 283414 A IL283414 A IL 283414A
Authority
IL
Israel
Prior art keywords
receptor
methods
conditions associated
treating conditions
treating
Prior art date
Application number
IL283414A
Other languages
English (en)
Hebrew (he)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IL283414A publication Critical patent/IL283414A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
IL283414A 2018-11-30 2021-05-25 Methods of treating conditions related to the s1p1 receptor IL283414A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773936P 2018-11-30 2018-11-30
US201962850464P 2019-05-20 2019-05-20
PCT/US2019/063413 WO2020112880A1 (en) 2018-11-30 2019-11-26 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
IL283414A true IL283414A (en) 2021-07-29

Family

ID=68966033

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283414A IL283414A (en) 2018-11-30 2021-05-25 Methods of treating conditions related to the s1p1 receptor

Country Status (9)

Country Link
US (1) US20220023258A1 (https=)
EP (1) EP3886841A1 (https=)
JP (2) JP2022511788A (https=)
KR (1) KR102824401B1 (https=)
CN (2) CN118649163A (https=)
AU (1) AU2019387212A1 (https=)
CA (1) CA3120706A1 (https=)
IL (1) IL283414A (https=)
WO (1) WO2020112880A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019252B1 (ru) * 2008-07-23 2014-02-28 Арена Фармасьютикалз, Инк. ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
SG10201906876PA (en) * 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN106063787A (zh) * 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
MX386419B (es) * 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3355896A2 (en) * 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
MA47504A (fr) * 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive

Also Published As

Publication number Publication date
KR20210098487A (ko) 2021-08-10
US20220023258A1 (en) 2022-01-27
JP2025024035A (ja) 2025-02-19
KR102824401B1 (ko) 2025-06-25
AU2019387212A1 (en) 2021-06-24
CN113226307A (zh) 2021-08-06
EP3886841A1 (en) 2021-10-06
WO2020112880A1 (en) 2020-06-04
CA3120706A1 (en) 2020-06-04
CN118649163A (zh) 2024-09-17
JP2022511788A (ja) 2022-02-01

Similar Documents

Publication Publication Date Title
IL280913A (en) Novel methods
IL283414A (en) Methods of treating conditions related to the s1p1 receptor
IL280912A (en) Novel methods
IL255461A (en) Anti-transferrin receptor antibodies with tailored affinity
EP3863043A4 (en) SUSCEPTOR
DK3242666T5 (da) Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren
PL3283110T3 (pl) Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
DK3849537T3 (da) Kombinationsterapier
EP3763567A4 (en) SEAT
DK3737403T5 (da) Modificerede adenovira
IL284114A (en) Methods of treating conditions related to the s1p1 receptor
PT3579826T (pt) Métodos de tratamento de distúrbios de cdkl5 com o composto ov329
EP3843832C0 (en) NEUROMODULATION SYSTEM
IL279180A (en) Methods of treating conditions related to the S1P1 receptor
EP3876776C0 (en) CONNECTOR
IL272163A (en) Methods of treating myelodysplastic syndrome
IL281594A (en) Anti-klrg1 antibodies
EP3899155A4 (en) IMPROVED CONNECTOR
EP3813610A4 (en) Locking mechanism
DK3617431T3 (da) Lås
EP3799000A4 (en) Unlocking system
CL2018000755S1 (es) Cerradura
EP3811824A4 (en) SEAT
EP3843748C0 (en) COMBINATION THERAPY
PL3880011T3 (pl) Sposób